RegenCell BioScience Holdings (RGC)

[shinhari1309]

Regencell Bioscience - a Traditional Chinese Medicine Company and Philanthropist CEO

Regencell Bioscience Holdings Limited (Nasdaq: RGC) is an early-stage bioscience company that focuses on the R&D and commercialization of Traditional Chinese Medicine (”TCM”) for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder (”ADHD”), Autism Spectrum Disorder (”ASD”), and infectious diseases affecting people’s immune system such as COVID-19.

In latest findings, Regencell Bioscience’s (TCM) has treatment formula has so far treated 12 / 19 patients (suspected or confirmed COVID cases), and their health records showed improvements after an average treatment period of 5 days.

The company’s CEO and chairman noted “While the research is still ongoing, we strongly believe that our formula can make a difference in the fight against COVID-19."

The company’s current plan is to trade, manufacture, market and distribute the TCM formulae for the treatment of COVID-19 to ASEAN countries, India, Japan, Australia and New Zealand.

Aside from the Company’s mission to threat people with ADHD and ASD, the company CEO, Mr Au is also involved in his own philanthropic project (within personal capacity) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.

[https://www.biospectrumasia.com/news/48/18957/regencell-bio-to-offer-traditional-medicines-for-covid-19-treatment-in-asean-countries.html]

[https://www.morningstar.com/news/business-wire/20220516005531/regencell-bioscience-holdings-limited-announces-over-5-million-ordinary-share-purchases-by-ceo]